Complications and comorbidities associated with antineoplastic chemotherapy:Rethinking drug design and delivery for anticancer therapy  

作　　者：Xiaoman Mao Shuang Wu Dandan Huang Chong Li 

机构地区：[1]College of Pharmaceutical Sciences,Southwest University,Chongqing 400715,China [2]Medical Research Institute,Southwest University,Chongqing 400715,China [3]School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China

出　　处：《Acta Pharmaceutica Sinica B》2024年第7期2901-2926,共26页药学学报（英文版）

基　　金：supported by the National Natural Science Foundation of China(NSFC No.82373808);Chongqing Science Fund for Distinguished Young Scholars(CSTB2023NSCQ-JQX0021,China);Fundamental Research Funds for the Central Universities(SWURC2020001,China);the project for Chongqing University Innovation Research Group,Chongqing Education Committee(CXQT200006,China).

摘　　要：Despite the considerable advancements in chemotherapy as a cornerstone modality in cancer treatment,the prevalence of complications and pre-existing diseases is on the rise among cancer patients along with prolonged survival and aging population.The relationships between these disorders and cancer are intricate,bearing significant influence on the survival and quality of life of individuals with cancer and presenting challenges for the prognosis and outcomes of malignancies.Herein,we review the prevailing complications and comorbidities that often accompany chemotherapy and summarize the lessons to learn from inadequate research and management of this scenario,with an emphasis on possible strategies for reducing potential complications and alleviating comorbidities,as well as an overview of current preclinical cancer models and practical advice for establishing bio-faithful preclinical models in such complex context.

关 键 词：COMPLICATIONS COMORBIDITIES CHEMOTHERAPY Preclinical cancer models Drug design Drug delivery 

分 类 号：R730.6[医药卫生—肿瘤]